Dev4All and Pharmaseed Join Forces in Commercial Cooperation to Boost Preclinical Development Services

LILLE, France & PARIS--(BUSINESS WIRE)--Nov 28, 2024--

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241127719655/en/

Dev4All, 4P-Pharma's cutting-edge R&D booster, announces a strategic collaboration with Pharmaseed, an established Contract Research Organization (CRO) with over 20 years of expertise in preclinical drug development.

This partnership combines the strengths of both organizations to offer an integrated, end-to-end approach for preclinical development. Together, Dev4All and Pharmaseed aim to deliver comprehensive and competitive solutions that accelerate drug development and address the complexities of today’s R&D landscape.

With over two decades of experience in CRO services and ten years advancing drug development candidates from TRL3 to TRL5, this close cooperation provides tailored preclinical support, cutting-edge laboratory capabilities, and strategic expertise, complementing clients’ R&D efforts worldwide.

Revital Rattenbach, Executive Chair of Dev4All, said: "I am thrilled about the new collaboration between Dev4All and Pharmaseed, which marks an exciting step forward in our shared commitment to innovation. This commercial cooperation empowers us to scale our capabilities, elevate our global impact, and deliver tailor-made solutions that meet our client's needs while maintaining the highest standards of scientific rigor."

Shmuel Landau, Co-CEO of Pharmaseed, said: "This collaboration with Dev4All is an excellent opportunity to expand our European presence and integrate our comprehensive preclinical solutions with DEV4ALL innovative R&D platform. Together, we are committed to deliver top-tier services, ensuring clients achieve their scientific and clinical milestones."

About Dev4All:
Dev4All, powered by 4P-Pharma, is an R&D booster designed to provide a wide range of preclinical solutions. With a decade-long foundation in preclinical research, Dev4All is committed to transforming innovative ideas into clinical-stage candidates through collaboration and scientific excellence.

Dev4All and Pharmaseed Join Forces in Commercial Cooperation (Graphic: Business Wire)

SAN FRANCISCO (AP) — Oklahoma City Thunder star Jalen Williams exited Wednesday's game against the Golden State Warriors with a right eye injury shortly before halftime and didn't return.

Williams went down grabbing at his eye after Jonathan Kuminga dunked over him with 39 seconds left in the first half. The Thunder forward stayed on the floor for a short time before he limped to the locker room with help. He was seen with an ice bag on the area during halftime.

Coach Mark Daigneault said after the Thunder's 105-101 victory he had no further details on Williams' status.

“I have no update on it, and I’ll just leave it at that for now,” Daigneault said.

In 16 minutes of action, Williams had 13 points, seven assists, six rebounds and a pair of steals, helping the Thunder to a 62-50 lead at intermission.

Williams is second on the Thunder averaging 22.1 points per game and leads the team with 6.5 rebounds and 2.2 steals per game.

AP NBA: https://apnews.com/hub/nba

Oklahoma City Thunder forward Jalen Williams (8) shoots in front of Golden State Warriors forward Lindy Waters III during the first half of an NBA basketball game Wednesday, Nov. 27, 2024, in San Francisco. (AP Photo/Godofredo A. Vásquez)

Oklahoma City Thunder forward Jalen Williams (8) reacts during the first half of an NBA basketball game against the Golden State Warriors, Wednesday, Nov. 27, 2024, in San Francisco. (AP Photo/Godofredo A. Vásquez)